{"id":"NCT00474630","sponsor":"Orexigen Therapeutics, Inc","briefTitle":"A Safety and Efficacy Study Comparing Naltrexone SR/Bupropion SR and Placebo in Obese Subjects With Type 2 Diabetes","officialTitle":"A Multicenter, Randomized, Double Blind, Placebo Controlled Study Comparing the Safety and Efficacy of Naltrexone 32 mg Sustained Release (SR)/Bupropion 360 mg Sustained Release (SR) and Placebo in Obese Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-05","primaryCompletion":"2009-06","completion":"2009-06","firstPosted":"2007-05-17","resultsPosted":"2014-11-21","lastUpdate":"2014-11-21"},"enrollment":505,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Obesity","Overweight","Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"Naltrexone SR 32 mg/bupropion SR 360 mg/ day","otherNames":["NB32"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"BEHAVIORAL","name":"Ancillary therapy","otherNames":[]}],"arms":[{"label":"NB32","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is determine whether the combination of naltrexone SR and bupropion SR is safe and effective in treating obesity in subjects with type 2 diabetes.","primaryOutcome":{"measure":"Co-primary: Body Weight- Mean Percent Change","timeFrame":"Baseline, 56 weeks","effectByArm":[{"arm":"NB32","deltaMin":-5.03,"sd":0.34},{"arm":"Placebo","deltaMin":-1.75,"sd":0.43}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":21,"exclusionCount":25},"locations":{"siteCount":53,"countries":["United States"]},"refs":{"pmids":["24144653"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":333},"commonTop":["Nausea","Constipation","Diarrhoea","Vomiting","Headache"]}}